It’s suddenly ‘hot’ to discuss gut diseases; doctors clamoring for more clarity on Paxlovid prescribing

In a reflection of a broader cultural moment, people are talking about their gastrointestinal problems, without shame, and with vigor. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      From social media to pink billboards, it's suddenly 'hot' to discuss gut diseases By Isabella Cueto BelliWelli In a reflection of a broader cultural moment, people are talking about their gastrointestinal problems, without shame, and with vigor. Read More Doctors are clamoring for more clarity on Paxlovid prescribing amid Covid-19 rebound concerns By Edward Chen Alex Welsh/The New York Times Six months after the emergency use authorization of Paxlovid for high-risk Covid patients, physicians say prescribing still isn't clear-cut. Read More STAT+: In the search for an ARPA-H director, the White House is zeroing in on DARPA veterans By Lev Facher Michael Reynolds/AP Francis Collins is making progress in finding a director for ARPA-H, and he’s turned to a natural proving ground for candidates: DARPA. Read More Sponsor content by STAT Events Democrats’ Last Chance for Drug Pricing Reform? The drug pricing debate remains a central conversation in Congress. On July 20, STAT sits down with key decision-makers about the latest developments from Capitol Hill and the White House. Join them. Former Theranos exec Ramesh Balwani convicted of fraud By Associated Press Ramin Rahimian/Getty Images A jury has found former Theranos executive Ramesh "Sunny" Balwani guilty on 12 felony counts of defrauding investors and patients. Read More STAT+: Here's what Democrats changed in their latest drug pricing bill By Rachel Cohrs Sarah Silbiger/Getty Images Senate Democrats have put final tweaks on their drug pricing proposal, as they race to achieve one of their signature domestic policy promises Read More STAT+: In a high-profile misstep, the FDA backtracks on its ban on Juul By Nicholas Florko Justin Sullivan/Getty Images Did the FDA miss 6,000 pages of data from Juul when it decided to ban the company’s e-cigarettes? STAT unpacks the latest in the saga. Read More STAT+: With 'do-over' NASH results, Intercept will seek approval for first-ever treatment for fatty liver condition By Adam Feuerstein Hyacinth Empinado/STAT An extensive re-analysis of a large clinical trial involving its experimental treatment once again achieved its primary efficacy goal. Read More Listen: VC malaise, FDA confusion, & yet another Alzheimer's debate By Damian Garde and Adam Feuerstein STAT's Allison DeAngelis joins us to explain how the prolonged downturn for biotech stocks is stoking anxiety among venture capitalists. Read More Opinion: Hospitals and for-profit PBMs are diverting billions in 340B savings from patients in need By Ted Okon APStock Nonprofit hospitals and for-profit 340B contract pharmacies are diverting billions of dollars that should be helping patients in need. Read More Thursday, July 7, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser